MORRISVILLE, N.C., Nov. 22 /PRNewswire/ -- etrials Worldwide, Inc., a leading provider of eClinical software for the efficient collection, cleaning, integration and review of data in the clinical trial process, today announced that it is in advanced discussions with Quintiles Transnational Corp., the leading provider of services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries, regarding a three- year licensing and technology sharing agreement with etrials related to post- approval studies. In addition to the proposed licensing commitment and technology, etrials would perform existing and future post-approval e-clinical client work to be run on the joint technology platform.
Under the proposed terms, Quintiles would execute a three-year subscription license for etrials’ fully integrated suite of eClinical tools including WebCapture, patient diaries and interactive voice response (IVR). etrials and Quintiles would also jointly develop a post-approval data capture and trial management system that would further integrate both companies’ technologies to offer Quintiles’ clients a seamless portal for the review and reporting of critical data throughout the trial process. This Phase IV toolset would combine etrials’ eClinical suite and Quintiles’ GoCRF and SMAART technologies to offer an integrated platform designed specifically for Quintiles customers conducting post-approval studies.
“We chose etrials to partner with because after extensively looking at many competing products, we felt etrials had the most comprehensive and mature product platform in the market,” said Dr. Hugo Stephenson, president of Strategic Research Services for Quintiles. “As safety surveillance and other forms of post-approval research are attracting growing industry attention, we believe etrials is well-positioned to support the technology scalability we need for our strategic research systems. Quintiles and etrials plan to aggressively develop an integrated product portfolio to promote safety and efficiency in post-approval trials.”
“Through its adoption of new technology and process improvements, Quintiles has continued to be a leader in the electronic clinical trial industry,” said John Cline, CEO of etrials. “With this partnership, we have the opportunity to join forces to offer technology specifically tailored for post-approval studies. This agreement would even further strengthen our eClinical platform as the broadest and most flexible set of tools in the market.”
About Quintiles Transnational Corp.
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world’s leading pharmaceutical services organization. For more information visit the company’s Web site at http://www.quintiles.com/ .
About etrials Worldwide, Inc.
etrials has earned the loyalty of its healthcare partners by guiding them to simplify and accelerate the way they manage clinical trials, educate markets and collect pre- and post-approval data on drug efficacy and safety. etrials offers an efficient eClinical platform for integrating clinical data from a variety of sources and allowing secure, real-time reporting of results through Web-based interfaces. etrials also provides experienced clinical consultation services to companies seeking to migrate from paper-based to electronic methods, leading them through the critical processes involved in turning a technology into a solution. To date, our team of professionals has participated in over 400 clinical trials in more than 50 different countries, including 12 trials that were used to attain NDA/BLA status.
etrials invites you to challenge the way you think about electronic clinical trials at http://www.etrials.com/ .
This press release contains “forward-looking statements.” These forward- looking statements involve risks and uncertainties that could cause actual results to differ materially, including the possibility that agreements relating to the proposed arrangements may not be completed in the near term or at all, the failure of any conditions necessary to complete the arrangements, potential changes in the terms, so that the final agreements differ from the terms described above, and potential difficulties in integrating the technologies and implementing the platform for its intended use and acceptance of the new platform by Quintiles’ and etrials’ customers.
etrials Worldwide, Inc.
CONTACT: Lorra Gosselin of etrials Worldwide, Inc., +1-919-653-3400, orpr@etrials.com
